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Abstract
O,O’-diethyl-(S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoate (DE-EDCP) is novel substance with cytotoxic 
activity in human leukemic cells. The aim of this study has been to predict in vivo bioavailability of the DE-EDCP and 
its potential metabolite (S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoic acid (EDCP) by in vitro characteriza-
tion which includes determination of lipophilicity and passive membrane permeability. There has also been evaluated 
inter-laboratory reproducibility of the bio-analytical method which was previously developed and validated for non-clin-
ical study of the DE-EDCP and EDCP.
Distribution coefficient n-octanol/water was 1.68 and 0.03, and apparent permeability coefficient was 4 × 10–4 cm/s 
and 20 × 10–4 cm/s, for the DE-EDCP and EDCP, respectively.
Observed results have shown that the DE-EDCP is more lipophilic with better membrane retention, but the EDCP 
has better pass through the membrane. Also, there has been demonstrated a reproducibility and robustness of the pro-
posed bio-analytical method.
Keywords: Transfer of the UHPLC-MS/MS, cross validation, (S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl) propanoic 
acid esters, membrane permeability, lipophilicity
1. Introduction
Cytotoxic activity of the novel ester derivatives of the 
(S,S)-1,2-ethanediamine-N,Nʹ-di-2-(3-cyclohexyl)propa-
noic acid has been previously proven by the in vitro studies 
on various leukemic cell lines. It was demonstrated that 
methyl, ethyl, and n-propyl esters are toxic to HL-60, REH, 
MOLT-4, KG-1, JVM-2, and K-562 leukemic cell lines, 
while the non-esterified compound and the n-butyl ester 
are devoid of cytotoxic action. The O,O’-diethyl-(S,S)-eth-
ylenediamine-N,N’-di-2-(3-cyclohexyl)propanoate dihy-
drochloride (DE-EDCP), has showed the highest cytotoxic 
activity on leukemic cell line HL-60 (IC50  in the range of 
11 μM – 45 μM). Demonstrated data show that the toxicity 
is mediated by the caspase-independent apoptosis associ-
ated with oxidative stress, mitochondrial dysfunction, and 
AIF translocation.1 DE-EDCP has been chosen for further 
characterization since it had exerted the strongest cytotox-
ic activity in HL-60 cell line.
In vitro characterization of new pharmaceutical 
substances includes determination of a lipophilicity and 
passive membrane permeability. These physicochemical 
properties of pharmaceutical substances are providing sig-
nificant information for prediction of the in vivo bioavail-
ability by exploring absorption and distribution behaviour 
of the substance. Lipophilicity is one of many factors in-
volved in biological activity of a drug, and it is often one of 
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the most influential.2 Lipophilicity is usually expressed by 
the n-octanol/water partition coefficient (logP) for neutral 
molecules and the distribution coefficient (logD) for ion-
ized molecules.3 Method for a determination of the LogD 
is based on determination of the n-octanol/water partition 
coefficient.2 This procedure requires the measurement of 
the compound concentration in n-octanol and water phas-
es after equilibration of both phases according to Eq. (1). 
Thus, the Eq. (1) can be written as:4 
logD = log (coctanol/cwater)    (1)
where coctanol and cwater are the concentrations of a substance 
in n-octanol and aqueous phase of the partition, respec-
tively.
Method for the in vitro prediction of passive mem-
brane permeability that can be used, is the parallel artifi-
cial membrane permeability assay (PAMPA). This method 
is used extensively for the early drug candidate evaluation. 
PAMPA was first introduced by Kansy et al.5–8 
This method has been shown useful in assessing 
trans-membrane, non-energy dependent, and diffusion of 
drugs in such a way that a reasonable predictability with in 
vivo (passive) absorption is possible. 
The artificial membrane permeability may be ex-
pressed either as a percent of transport (%T) or as an ap-
parent permeability coefficient Papp. 
%T = 100 · (AR ·VR)/ (AD0 · VD)    (2)
Where AD0 and AR are the peak areas of the initial 
donor solution and the post-incubation receiving solution 
(from the acceptor wells), VR and VD are the volumes of the 
receiving and donor solutions.
The %T is related to Papp based on the following equa-
tion:
Papp =  (VD · VR) / ((VD + VR) · S · t) · ln[(100 · VD)  
/ (100 · VD – %T (VD + VR))]   
(3)
Where S is the surface area of the artificial mem-
brane and t is the incubation time.5
Generally, compounds that have a Papp < 10 × 10-6cm/
s are classified as low permeability and ones with a Papp > 10 
× 10-6cm/s are classified as high permeability.
In vivo characterization of new pharmaceutical 
substances includes non-clinical study on animal mod-
el. For non-clinical study of cytotoxic activity of the 
DE-EDCP and its potential metabolite (S,S)-ethylenedi-
amine-N,N’-di-2-(3-cyclohexyl)propanoic acid dihydro-
chloride (EDCP), there has been  previously developed and 
validated the ultra-high performance liquid chromatogra-
phy tandem mass spectrometry (UHPLC-MS/MS) bio-an-
alytical method.9 Bioanalytical methods should be robust.10 
Evaluation of reproducibility (transferability) of bio-analyt-
ical method is becoming increasingly important11–13  since 
the bio-analytical methods are often used in different labo-
ratories during non-clinical and clinical studies. The transfer 
process requires  the procedure to be physically transferred 
from a laboratory which masters the technique (called 
sender or originator) to another site (called receiver or re-
cipient).14 In the context of bio-analysis, method transfer is 
covered by the Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) guidance documents 
on bio-analytical method validation.11,13,15 Although the 
need for method transfer is recognized by both authorities, 
little is said about the process itself. Several approaches have 
been described for the method transfers evaluation.12,16–24
New UHPLC-MS/MS bio-analytical method which 
has been developed and validated for the in vivo character-
ization (non-clinical study) of the DE-EDCP and EDCP9, 
is supposed to be used in different laboratories during the 
mentioned studies. However, in vitro characterization (li-
pophilicity and membrane permeability) of the DE-EDCP 
and EDCP has not been investigated until now. 
The aim of this study is to predict the in vivo bioavaila-
bility of the DE-EDCP and its potential metabolite EDCP by 
the in vitro characterization – determination of lipophilicity 
and passive membrane permeability. In this study, there has 
also been evaluated the inter-laboratory reproducibility of 
the previously mentioned bio-analytical method.
2. Experimental
2. 1. Chemicals
O,O’-diethyl-(S,S)-ethylenediamine-N,N’-di-2-(3-cy-
clohexyl)propanoate (DE-EDCP), (S,S)-ethylenediami ne-
N,N’-di-2-(3-cyclohexyl)propanoic acid dihydrochloride 
(EDCP) and the internal standard (S,S)-O,O’-dibutyl-1,3-
propanediamine-N,N’-di-2-(3-cyclohexyl)propanoate dihy-
drochloride (DB-PDCP), were provided by the Faculty of 
Chemistry, University of Belgrade, Serbia (Table 1).
Acetonitrile, methanol, ethyl acetate, diethyl ether, 
triethanolamine, chloroform and trifluoroacetic acid 
(HPLC grade), ammonium acetate (CH3COONH4), so-
dium fluoride and KH2PO4 (ACS grade) from Fluka 
(Sigma-Aldrich Co.), n-octanol from Fluka AG (Buchs 
SG, Switzeland) and deionized water (TKA GenPure Ul-
trapure, Germany), were used. Mouse serum was pur-
chased from Sigma Aldrich (Saint Louis, USA).
2. 2. Solutions
Preparation of all standard solutions is described in 
a previously published study.9 Sample preparation is also 
described previously.9All these solutions were prepared by 
two different analysts in sending and receiving laboratories.
2. 3. Equipment
Solids were weighted by using a 5-digit Mettler an-
alytical balance (Mettler-Toledo International Inc, USA), 
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and less sensitive weighting was performed on the Ad-
venturer Pro analytical balance (OHAUS, USA). Sample 
preparation was done by using the Eppendorf 5417R mi-
cro-centrifuge (Eppendorf, Germany).
2. 4. Sending Laboratory
Development and validation of the method was done 
in the sending laboratory on the Thermo ACCELA (Ther-
mo Scientific, Waltham, Massachusetts, USA) UHPLC sys-
tem, coupled to a triple quad Mass Spectrometer Thermo 
TSQ Quantum Access Max (Thermo Scientific, Waltham, 
Massachusetts, USA),  with a heated electro-spray ioniza-
tion (HESI) interface.24 A reverse-phase Thermo Scientific 
Hypersil GOLD aQ column (100 × 2.1 mm 1.9 μm Ther-
moScientific, and guard cartridge (Thermo Scientific Hy-
persil GOLD aQ, 10 mm l × 4 mm ID), were used in both 
laboratories.
2. 5. Receiving Laboratory
In the receiving laboratory, method transfer and 
validation were carried out on the Agilent 1290 UHPLC 
system equipped with the Agilent 6420 triple-quad mass 
detector (Agilent Technologies, Santa Clara, USA) with 
the electro-spray ionization (ESI) interface. 
DE-EDCP, EDCP and IS were eluted by using a 
mobile phase as previously described.9 Quantitation was 
achieved by the MS–MS detection in the positive ioniza-
tion mode for the DE-EDCP, EDCP and IS. The MS oper-
ating conditions were optimized as following: the capillary 
voltage was 4500 V, the gas temperature was set to 340 °C 
and gas flow was 10 l/min and the nebulizer pressure was 
35 psi. Nitrogen was used as a collision gas. Fragmented 
voltage was set to 135 V. Ions detection was performed 
in the multiple reaction monitoring (MRM) by using the 
following transitions of m/z 425.2 → 197.8 and 226.1 for 
DE-EDCP, m/z 369.3 → 152.1 and 198.1 for EDCP and m/z 
495.3 → 166.0 and 268.1 for DB-PDCP (IS), respectively, 
with a scan time of 0.1 s per transition.
Mass Hunter Optimizer software version 6.00 (Ag-
ilent Technologies, Santa Clara, USA) was used for auto-
matic optimization of the acquisition parameters. Data 
Acquisition was performed by using the Mass Hunter Data 
Acquisition software version 6.00 (Agilent Technologies, 
Santa Clara, USA). 
Qualitative and quantitative data analyses were done 
by using the Mass Hunter Qualitative software version 
6.00 and Mass Hunter Quantitative software version 6.00 
(Agilent Technologies, Santa Clara, USA), respectively.
Method transfer was done from the sending labora-
tory to the receiving laboratory. 
The cross-validation samples were analyzed through 
a fully validated bio-analytical method at the receiving lab-
oratory along with the calibration of the standards and QC 
samples for the validity of each analytical run. The follow-
ing validation parameters were evaluated in the receiving 
laboratory for the UHPLC-MS/MS system: selectivity, lin-
earity, limit of quantification (LLOQ), recovery, accuracy, 
precision and matrix effects.
Also, cross-validation samples were analyzed by 
the Passing and Bablok regression analysis. Passing and 
Bablok regression analysis is a statistical procedure which 
allows the valuable estimation of the analytical methods 
agreement and possible systematic bias between them. Re-
sults are presented with a scatter diagram and a regression 
line, as well as a regression equation where an intercept 
represents a constant and slope proportional measure-
ment error. Confidence intervals of 95% of the intercept 
and slope, give the explanation whether their value differ 
from the value zero (intercept) and value one (slope) only 
by chance, allowing a conclusion of the method agreement 
and a correction action, if necessary.25
During this study, there have been tested the selectivity, 
linearity, limit of quantification (LLOQ), recovery (%), ma-
trix effects, accuracy and precision, as described previously.9
Table 1: Structure of EDCP, DE-EDCP, and the internal standard DB-PDCP
Name of compound Empirical Abbreviation MW R n
 formula  (g/mol)
(S,S)-ethylenediamine-N,N’-di-2-(3-cyclohexyl)propanoic C20H38O4N2Cl2 EDCP 441.43 H 2
   acid dihydrochloride
O,O’-diethyl-(S,S)-ethylenediamine-N,N’-di-2-C24H46O4N2Cl2 DE-EDCP 497.54 C2H5 2
   (3-cyclohexyl)propanoate dihydrochloride 
(S,S)-O,O’-dibutyl-1,3-propanediamine-N,N’-di-2- C29H56O4N2Cl2 DB-PDCP 567.67 C4H9 3
   (3-cyclohexyl)propanoate dihydrochloride
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Cross-validation showed to be successful in terms 
of the results’ traceability between the two instruments 
(slope and intercept with confidential interval values) and 
the results of validation parameters (selectivity, linearity, 
limit of quantification (LLOQ), recovery, accuracy, preci-
sion and matrix effects).
2. 6.  Determination of the n-octanol/water 
Distribution Coefficient (LogD) 
LogD values were determined by using a shake-flask 
method. In the shake-flask experiment, 5 mg of each sub-
stance (DE-EDCP and EDCP) was first mixed with 50 ml 
of aqueous buffer (pH 7.4). Then, 10 ml of this solution 
was mixed with 10 ml of the n-octanol (water saturated). 
The sample vial was placed on the shaker and been shaken 
for 12 h at 250 rpm. After equilibration, it was left to stand 
for 2 h to phases well separated. 
The separated aqueous phase is being centrifuged, 
the residual drops of the n-octanol to be eliminated. The 
aqueous phase was sampled and assayed by the transferred 
and cross-validated UHPLC-MS/MS which had been pre-
viously validated for the determination of the investigated 
substances in the aqueous buffer (pH 7.4) in order to de-
termine the logD value. The concentration of the investi-
gated substances in the n-octanol phase was obtained as 
a difference in the concentrations in the aqueous buffer, 
prior to mixing with the n-octanol and after mixing with 
the n-octanol.
2. 7.  Prediction of Membrane Permeability 
(PAMPA test)
The in vitro method for the prediction of membrane 
permeability which was used in these studies, was carried 
out in a 96-well format. 96-well micro-titer plates (hydro-
phobic PVDF MultiScreen IPFilter Plate 0.45 μm, from 
Milipore (Bedford, MA, USA)), were assembled into such 
a “sandwich” that each composite well was separated by a 
125 μm micro filter disc. Filter material in each well of the 
filtration plate was wetted with 5 μl of the artificial mem-
brane solution, which consisted of 1 % egg lecithin in the 
n-dodecane. Subsequently, the filter plate was placed on 
the bottom micro-titer plate containing the following do-
nor solution: 300 μl of the compound in the concentration 
of 0.1 mg/ml dissolved in the buffer KH2PO4 0.2M, pH = 
7.4. The top acceptor wells of the sandwich, were hydrated 
with the 300 μl of the buffer KH2PO4 0.2M, pH 7.4. To pre-
vent loss by evaporation, the system was first covered with 
a paraffinic film. The surface area of the artificial mem-
brane was S = 0.28 cm2 and the period of incubation was t 
= 7200 s (2 h).
After incubation, the amount of the DE-EDCP and 
EDCP in the donor and acceptor wells, was determined by 
the UHPLC-MS/MS method which had been previously 
transferred and cross-validated.
2. 8. Software
For the determination of lipophilicity (LogD7.4) of 
the investigated substances by the in silico model, there 
was used the MarvinSketch 4.1.13 (ChemAxon, Budapest, 
Hungary).
3. Results and Discussion 
3. 1.  UHPLC-MS/MS Method: Transfer and 
Cross-validation
Transfer of the ultra-high performance liquid chro-
matography-electro-spray tandem mass spectrometry 
(UHPLC-ESI-MS/MS) method for non-clinical studies 
and the in vitro characterization of recently synthesized 
substances with the cytotoxic activity, DE-EDCP and its 
potential metabolite EDCP, in biological material, was 
carried out. The reproducibility and transferability of this 
bio-analytical method in the mouse serum was evaluat-
ed by the validation and cross-validation of the method 
through using two different UHPLC-MS/MS systems. The 
parallel displayed values of the observed validation param-
eters are given in the Table 2.
The method was proven to be highly selective for the 
analytes, since no interfering peaks from the endogenous 
compounds were observed at the retention times for the 
DE-EDCP and EDCP in any of the six independent blank 
serum extracts evaluated.
Also, cross-validation samples analyzed by the Pass-
ing and Bablok regression analysis, showed to be successful 
in terms of the results’ traceability between the two instru-
ments (for DE-EDCP: slope = 0.9821 with lower 95 %-CL = 
0.7737 and upper 95%-CL = 1.1685, and intercept = 0.0547 
with lower 95 %-CL = -5.1662 and upper 95%-CL = 3.4285; 
for EDCP: slope = 1.0187 with lower 95 %-CL = 0.9522 and 
upper 95%-CL = 1.1505, and intercept = -0.0488 with lower 
95 %-CL = –0.5347 and upper 95%-CL = 0.2187).
Overall results of the cross-validation were satisfac-
tory in terms of all the investigated parameters proving 
that the method can be successfully transferred under the 
aforementioned conditions. Results of the validation and 
cross validation demonstrate that the novel UHPLC-MS/
MS method for the in vivo characterization (non-clinical 
study) of the novel DE-EDCP and EDCP substances with 
cytotoxic activity, is appropriately transferred and validat-
ed at the receiving laboratory.
3. 2.  Validation of the UHPLC-MS/MS in the 
Aqueous Buffer
The observed UHPLC-MS/MS method was success-
fully validated for the determination of the investigated 
substances DE-EDCP and EDCP from an aqueous buffer 
(pH 7.4). Results of the validation parameters are given in 
the Table 3.
63Acta Chim. Slov. 2018, 65, 59–64
Tubić et al.:   Prediction of in vivo Bioavailibility by in vitro Characterization   ...
Table 3: Validation parameters for the DE-EDCP and EDCP in an 
aqueous buffer, without a biological matrix (Thermo ACCELA)
Validation               Thermo ACCELA
parameter DE-EDCP EDCP
Linearity of 2.0 to 40.0 ng/ml 0.5 to 10.0 µg/ml
calibration curves r = 0.9930 r = 0.9997
LLOQ 2.0 ng/ml 0.50 μg/ml
Precision (%CV) 3.29 to 18.07% 6.09 to 15.50%
Accuracy (%RE) 0.01 to 16.00%  1.48 to 13.50%
3. 3.  Determination of the Log D7.4 in vitro/in 
silico and the PAMPA Test
Lipophilicity of the observed substances DE-EDCP 
and EDCP, has been tested by the traditional shake-flask 
method. Passive membrane permeability has been tested 
by the PAMPA test. Experimental results that have been 
obtained in this study are shown in the Table 4. Also, in the 
Table 4, there can be seen in silico results of the lipophilic-
ity of the DE-EDCP and EDCP.
Table 4: Lipophilicity and passive membrane permeability data for 
the investigated substances DE-EDCP and EDCP
Com- Log  Log Papp %T % Membrane
pound D7.4* D7.4 (cm/s)  retention
EDCP –1.8 0.03 20*10–4 7.94 6.90
DE-EDCP 4.04 1.68 4*10–4 1.76 97.46
* by MarvinSketch 4.1.13
The results represent obvious difference in the lipo-
philicity between the DE-EDCP and EDCP. Lipophilic-
ity data obtained through the shake flask method, and 
membrane permeability data acquired by the PAMPA 
test, are correlated with the results gained in the previous 
in vitro activity studies on various leukemic cell lines of 
the investigated compounds. Compound DE-EDCP with 
a significant cytotoxic activity,1 has greater lipophilicity 
which allows more retention in the cell membrane. This 
characteristic of the aforementioned compound is par-
ticularly important for its activity. On the other hand, 
the suspected metabolite EDCP is more hydrophilic and 
passes through the membrane, without retention in the 
cell membrane. 
4. Conclusions
In this study, DE-EDCP and EDCP bioavailability 
was examined through in vitro characterization, by deter-
mination of lipophilicity and passive membrane perme-
ability. Observed results are showing that the DE-EDCP 
is more lipophilic than the EDCP, with better membrane 
retention. 
Additionally, this study proved good reproducibility 
(transferability) and robustness of the bioanalytical meth-
od for in vivo characterization of the investigated sub-
stances.
5. Acknowledgements
This work was partly supported by the Ministry of 
Education, Science and Technological Development of the 
Republic of Serbia, as a part of the Projects No. 172041 
and No. 175035. One of the authors (B.T.) is thankful to 
the Ministry of Science and Technology of the Republic 
of Srpska for funding the study through the Project 19/6-
020/961-169/14.
Table 2: Validation parameters for the DE-EDCP and EDCP on the Thermo ACCELA and the Agilent 1290 UHPLC system
Validation parameter Sending laboratory (Thermo ACCELA) Receiving laboratory 
  (Agilent 1290 UHPLC system) 
 DE-EDCP EDCP DE-EDCP EDCP
Linearity of calibration curves 1.3  26.7 ng/ml 0.33–6.67 µg/ml 3.3–26.7 ng/ml 0.33–6.67 µg/ml
 y = 0.0461x + 0.0895,  y = 0.1527x + 0.0045,  y = 64.243x + 114.54, y = 9322.3x – 103.4,
 r = 0.9978 r = 0.9987 r = 0.9983 r = 0.9989
LLOQ 1.3 ng/ml 0.33 μg/ml 3.3 ng/ml 0.33 μg/ml
Recovery % 90.0–99.3 75.8–100.3 91.0–99.8 77.8–101.5
Matrix effect 95.5 – 108.2%  96.7–109.4% 
Precision (%CV) 15.99 5.58 3.22 4.00
 13.68 4.43 3.36 2.05
 2.25 5.32 3.97 3.95
 3.49 4.01 1.87 2.00
Accuracy (%RE) 3.01 6.06 17.05 –9.93
 12.61 –2.41 11.50 –14.52
 6.30 –3.20 5.20 –13.13
 1.80 –14.40 1.73 –14.20
y represents the peak area ratio of analyst to IS
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Povzetek
(S,S)-O, O-dietil-1,2-etandiamin-N,N‘-di-2-(3-cikloheksil)propanoat (DE-EDCP) je nova snov s citotoksično aktiv-
nostjo v človeških levkemičnih celicah. Cilj te študije je bil napovedovanje in vivo biološke uporabnosti DE-EDCP in 
njegovega potencialnega metabolita (S,S)-1,2-etandiamina-N,N‘-di-2-(3-cikloheksil) propanojske kisline EDCP) z in 
vitro karakterizacijo, ki vključuje določanje lipofilnosti in pasivne membranske prepustnosti. Ocenjena je bila med-
laboratorijska obnovljivost biološke analitske metode, ki je bila predhodno razvita in potrjena za neklinično študijo 
DE-EDCP in EDCP.
Porazdelitveni koeficient med n-oktanolom in vodo je bil 1,68 in 0,03, navidezni koeficient prepustnosti pa je bil 4 
× 10–4 cm/s in 20 × 10–4 cm/s za DE-EDCP in EDCP.
Opaženi rezultati so pokazali, da je DE-EDCP bolj lipofilen z boljšim zadrževanjem v membrani, medtem ko 
EDCP bolje prehaja skozi membrano. Lahko domnevamo, da je mehanizem citotoksične aktivnosti DE-EDCP na ravni 
celične membrane. Dokazana je bila ponovljivost in robustnost predlagane bioanalitične metode.
